Has onabotulinumtoxinA follow-up delay during COVID-19 lockdown affected the migraine course?

TitleHas onabotulinumtoxinA follow-up delay during COVID-19 lockdown affected the migraine course?
Publication TypeConference Paper
Year of Publication2021
AuthorsGonzalez-Martinez, A., Á. Planchuelo-Gómez, Á. L. Guerrero, D. García-Azorín, S. Santos-Lasaosa, M. P. Navarro-Pérez, P. Odriozola-González, M. Jesús Irurtia, S. Quintas, R. de Luis-García, and A. B. Gago-Veiga
Conference NameInternational Headache Congress 2021
Date Published2021
PublisherInternational Headache Society & European Headache Federation
Conference LocationVirtual Congress

Objective: During the COVID-19 pandemic face-to-face procedures have been postponed. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.
Methods: Subjective worsening, intensity of migraine attacks and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.
Results: We included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0%) female,
44.5 +- 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 8.4 and 8.1 less monthly days with headache (adjusted p = 0.011) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.
Conclusion: Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.